Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

Author： Cornely Oliver A   Pappas Peter G   Young Jo-Anne H   Maddison Philip   Ullmann Andrew J  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.2, 2011-03, pp. : 171-183

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Micafungin prophylaxis top in SCT

By  

Inpharma, Vol. 1, Iss. 1648, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Monoclonal antibodies for prophylaxis and therapy of infectious diseases

By Meulen Jan ter  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 4, 2007-11 ,pp. : 525-540

Informa Healthcare

Access to resources Recommend Favorite

Micafungin

By Jarvis B.   Figgitt D.P.   Scott L.J.  

Drugs, Vol. 64, Iss. 9, 2004-01 ,pp. : 969-982

Adis International

Access to resources Recommend Favorite

Safety of micafungin in infants: insights into optimal dosing

By Ascher Simon   Smith Phillip Brian   Benjamin Daniel K  

Expert Opinion on Drug Safety, Vol. 10, Iss. 2, 2011-03 ,pp. : 281-286

Informa Healthcare

Access to resources Recommend Favorite

Micafungin: A Review of its Use in the Prophylaxis and Treatment of Invasive Candida Infections

By Scott Lesley J.  

Drugs, Vol. 72, Iss. 16, 2012-11 ,pp. : 2141-2165

Adis International

Access to resources Recommend Favorite